Table 2. Recommendations of hematologic malignancies studies.

Author	Date of publication	Hematologic neoplasm	Recommendation
Percival et al [26]	5 May 2020	Not specified	SARS-CoV-2 testing are not routinely performed before standard chemotherapy Tests should be considered prior to SCT and CAR T-cell therapy
Paul et al [25]	11 May 2020	Leukaemia	SARS-CoV-2 testing for patients with CML on TKI or with CLL who will receive myelosuppressive chemoimmuno treatment, such as FCR or bendamustine plus rituximab; SARS-CoV-2 testing before allogenic SCT
Koffman et al [24]	30 April 2020	CLL	Survey with CLL specialist: considering an unlimited capacity of COVID-19 testing, 23% suggested for all patients; in a scenario with limited test availability, most specialists did not recommend universal testing and 62% suggested the test only to symptomatic patients
Perini et al [27]	17 April 2020	Lymphoid malignancies	Testing before treatment is unclear and testing strategy should be individualised
Al Saleh et al [28]	17 April 2020	MM	SARS-CoV-2 testing before starting treatment and autologous SCT
Malard et al [29]	27 April 2020	MM	SARS-CoV-2 testing before autologous SCT
Terpos et al [30]	13 May 2020	MM	SARS-CoV-2 testing before starting a new treatment line, or autologous SCT

Abbreviations: CAR = chimeric antigen receptor; CML = chronic myeloid leukaemia; CLL = chronic lymphocytic leukaemia;

FCR = fludarabine, cyclophosphamide, and rituximab; MM = multiple myeloma; SCT = stem-cell transplantation.